Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for hard-to-treat breast cancer: immune-boosting combo trial underway

NCT ID NCT03971409

First seen Apr 20, 2026 · Last updated May 24, 2026 · Updated 6 times

Summary

This study tests whether combining the immunotherapy drug avelumab with other medications can help people with advanced triple-negative breast cancer. About 145 adults with stage IV or inoperable breast cancer will receive one of several drug combinations. The goal is to see if these treatments can shrink tumors and improve outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Abramson Cancer Center, University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • Baylor College of Medicine

    Houston, Texas, 77030, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Duke Cancer Institute

    Durham, North Carolina, 27710, United States

  • Georgetown University

    Washington D.C., District of Columbia, 20057, United States

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • O'Neal Comprehensive Cancer Center

    Birmingham, Alabama, 35294, United States

  • Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University

    Baltimore, Maryland, 21218, United States

  • UNC Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina, 27599, United States

  • University of California, San Francisco

    San Francisco, California, 94143, United States

  • University of Chicago Medicine Comprehensive Cancer Center

    Evergreen Park, Illinois, 60805, United States

  • Vanderbilt University Ingram Cancer Center

    Nashville, Tennessee, 37232, United States

Conditions

Explore the condition pages connected to this study.